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ABSTRACT
BACKGROUND:
The incidence and prevalence of Chronic Kidney Disease is increasing slowly. The
affected groups are predominantly elderly individualS, diabetics and patients with
systemic hypertension. Peripheral Neuropathy among CKD patients is the most
common neurological complication of uremia, but still it is an under estimated
problem adversely affecting the patient’s quality of life.It is more often a silent
burden for the patient, progressively affecting his/her quality of life. It is sometimes
overlooked as the treating physicians are occupied with other uremia related
complications and also there is a dearth of literature regarding the diagnostic criteria
and management of this condition. It is further amplified by the lack of availability of
a simple screening tool for peripheral neuropathy in CKD. Hence this study aims to
establish the prevalence of peripheral neuropathy among patients with CKD in our
Hospital.
AIMS AND OBJECTIVES:
 To study the prevalence of peripheral neuropathy in patients with chronic
kidney disease in GVMCH.
 To determine the prevalence of Peripheral Neuropathy and associated factors
in relation to the stage of CKD.
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METHODOLOGY:
This study was carried out in chronic kidney disease patients attending hemodialysis
unit  and patients admitted as in-patients in our medical wards in the department of
General medicine, Government Vellore Medical College and Hospital. A total sample
of 100 patients were studied using meticulously prepared proforma over a period of
one year starting from October 2016 to September 2017. After prior Institutional
Ethical clearance and obtaining informed consent, the participants satisfying the
inclusion criteria were asked detailed history and clinical examination was performed
according to the well-designed proforma cited below. The presence of neuropathy
was assessed using Michigan Neuropathy Screening Instrument (MNSI) Scores with
Semmes-Weinstein monofilament(10g) and Diabetic neuropathy symptom
score(DNS).Weight,height  and waist of the individual patients were measured and
BMI was calculated and recorded in all the cases.
RESULTS:
The mean age of the study subjects was 47.87 years. Most of the patients
belonged to the age group 40-70years.Out of 100 cases,there were 58 (58.0%) males
and 42(42.0%) females.The Male to Female sex ratio was 1.38:1.Sixty patients out of
100 patients were on Hemodialysis whereas 40 patients belonged to the non-HD
group. The prevalence of peripheral neuropathy in CKD patients in GVMCH
assessed by MNSI was 64%.The prevalence of clinical Uremic distal symmetrical
sensory-motor peripheral neuropathy assessed by MNSI in the CKD on HD
population was 71.66%. Whereas the prevalence for the same for CKD patients not
on HD was 73.68%.Of the non-HD patients  6 out of 17 CKD stage 4
patients(35.29% prevalence) and 1 out of 4 CKD stage 3 patients (25% prevalence)
xwere affected by peripheral neuropathy.The average height of the study population
was 162.77cm. The average weight of the study population was 61.60kg.The average
BMI of the study population was 23.05.The average eGFR of the study population
was 13.05ml/min/1.73m2BSA. The average serum creatinine of the study group was
5.33mgs%.
CONCLUSION:
Uremic neuropathy is the most common neurological complication in patients with
uraemia.
The condition is not restricted to patients with ESRD,but it is more prevalent in
patients with stage V CKD. MNSI physical assessment could be used as a simple bed
side examination to determine the presence or absence of uremic peripheral
neuropathy.
Keywords : Chronic Kidney Disease, Michigan neuropathy screening
instrument, Peripheral neuropathy, Uremic neuropathy.
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1INTRODUCTION
In the ever changing field of medicine, chronic kidney disease and its complications
are on the uptrend in terms of incidence and prevalence and remains as a major cause
of morbidity and mortality in developing and developed nations alike. It will remain
to be so in the forth coming years. Much emphasis has been placed on the increased
cardiovascular risk and electrolyte abnormalities that accompany chronic kidney
disease but uremic neuropathy as a complication has always received less attention.
The dreaded neurological complication is usually the uremic encephalopathy or a
vascular event that accompanies hypertension.
The term uremic neuropathy denotes neuropathy either central or peripheral that is
due to the extended effects of the spectrum of uraemia, a condition that loosely
translates to accumulation of organic waste products that would be actively filtered
by a normal kidney1.
Asbury KA1 in his own words said “The fact that chronic renal failure may be
associated with polyneuropathy is not generally appreciated and is practically not
documented in the medical literature. In the briefest possible terms, the neurological
disease may be defined as follows: It began with painful burning sensation of the feet,
followed by slowly progressive numbness and weakness. The feet and legs were
affected more than the hands and arms, and the distal segments more than the
proximal”. It was only after this our understanding of uremic peripheral neuropathy
gradually increased.
Withstanding the therapeutic advances, most neurological complications of the
uremic state fail to respond adequately to treatment.Despite routine haemodialysis,
many neurological complications seldom improve in majority of the cases.
2A vast spectrum of pathophysiological processes are included in chronic kidney
disease (CKD), which almost always progressively lead to abnormal kidney function
along with  worsening glomerular filtration rate. The development of neuropathy is
most common when eGFR falls below 12mL/minute/1.73m2 BSA2,3.
The estimated prevalence of CKD in India is around 0.78% -0.8%3,4. The rate of
which is increasing slowly1. A rough age adjusted incidence of CKD stage V or End
Stage Renal Disease (ESRD) is around 151 and 232 per million population
respectively5. Uraemia is a clinical syndrome involving abnormalities with fluid,
electrolyte, hormone balance and metabolic abnormalities. These abnormalities
develop in parallel to the deterioration of renal function.
Uremic peripheral neuropathy is one of the severe and disabling complications in
patients with chronic kidney disease. Charcot6 in 1880 suspected the existence of
uremic neuropathy and Nearly more than half a century later, after the introduction of
haemodialysis and renal transplantation in the early 1960s the investigations gathered
steam. Uremic neuropathy encompasses a wide variety of manifestations of which
distal symmetrical sensory motor peripheral neuropathy is the commonest. The
severity of uremic peripheral neuropathy increases with decrease in glomerular
filtration capacity. The neuropathy is a dying back neuropathy or central-peripheral
axonopathy associated with secondary demyelination. The clinical and pathological
features of uremic peripheral neuropathy were described in detail by Adams, Victor
and Asbury in 1962. Dyck7 and colleagues established the current concept of uremic
neuropathy in 1971 on the basis on their wide nerve conduction studies in vivo and in
vitro and on light and electron microscopy8. They were able to demonstrate axonal
shrinkage with quantitative histology. Myelin sheaths were involved out of proportion
to axonal involvement. The dysfunction of the neuron resulted in a decrease in the
3diameter of the axon, rearrangement of myelin, and in the end complete degeneration
of the axon. The uremic peripheral neuropathy manifestation in patients are variable
ranging from paraesthesia, pain, weakness and atrophy of lower limbs, muscle
cramps, restless legs to sometimes features mimicking Guillain-Barre like.
Renal replacement therapy has resulted in halting of the symptoms of uremic
peripheral neuropathy or even reversal but sometimes there might not be any
improvement at all. The rate of reversibility depends on various parameters such as
duration of symptoms, type of renal replacement therapy, frequency of dialysis and so
on. Renal transplant provides the best possible results out of all the current therapies
available aimed at alleviating uremic peripheral neuropathy. This study is primarily
aimed at estimating the prevalence of peripheral neuropathy in patients with CKD in
a tertiary care hospital including those on renal replacement therapy.
4AIMS AND OBJECTIVES
1. To study the prevalence of peripheral neuropathy in patients with chronic
kidney disease in GVMCH.
2. To determine the prevalence of Peripheral Neuropathy and associated factors
in relation to the stage of CKD.
5REVIEW OF LITERATURE
INCIDENCE:
Though the occurrence of peripheral Neuropathy in patients with renal failure has
been known for over a Century, it was not fully recognized till the middle of the 20th
century. Before the implementation of chronic dialysis for patients with ESRD, the
patients usually did not survive long enough to develop peripheral neuropathy that
can be clinically diagnosed. Up to 65% of the patients develop Peripheral neuropathy,
before or in a short span of time after putting them on dialysis. Nielsen studied 109
patients with CRF in Denmark, out of which 84 complained of symptoms and 56
developed signs of peripheral neuropathy9. Whereas, according to Bolton and Young
10% to 83% of those with CRF developed clinically appreciable neuropathy10. Men
are more frequently affected than women. According to Nielsen, the men:women
ratio was 60:49, out of 109 patients9. The reason behind this male preponderance is
not understood yet.  The occurrence of neuropathy has no association with serological
and biochemical abnormalities (urea, creatinine, calcium, etc.) but has correlations
with the duration and severity of renal failure10,11. Unlike sexual preponderance, there
are no reported studies to establish the role of race.Patients of all age groups can be
affected if the degree of renal failure is well established.
ETIOLOGY OF UREMIC NEUROPATHY
The exact metabolic abnormality causing Uremic neuropathy is yet unknown.A
number of observations have been made with regards to potential urotoxins that can
cause peripheral neuropathy.Some of the few identified toxins are guanidine
compounds, parathyroid hormone, middle molecules, myoinositol and so on.They are
implicated but are not established causes of peripheral neuropathy12.
6Many had attempted to find the offending urotoxin that is precisely elevated in CKD
patients causing peripheral neuropathy.In the initial days of renal replacement therapy
the concept of ‘middle molecules’ as the likely candidate for causing uremic
neuropathy was put into focus12,13. Though the proof was mainly observational, the
concept stayed for a quite a long time14. The observation that dialysis considerably
improves the uremic symptoms only augmented the speculation that schribner
postulated that the compounds causing neuropathy should be the middle molecules
with molecular weight ranging between 500 to 2000 Daltons. These compounds are
however larger than Urea and Creatinine and so are cleared by dialysis at a much
lower rate than urea and creatinine which are the usual measure of biochemical
control of uraemia. This postulation is strengthened by the facts that the occurrence of
uremic neuropathy is decreased by subjecting the patient to more number of cycles of
dialysis in a week.Hemodialysis with 3 cycles a week has been able to bring about an
abrupt halt in the progression of neuropathy but nevertheless the improvement was
very minimal or negligible, whereas patients on peritoneal dialysis were able to
experience a significant improvement in symptoms even without improvement in
biochemical parameters like urea and creatinine.This could be due to the fact that the
peritoneum is able to filter the middle molecules much more efficiently than the
semisynthetic membranes used in hemodialysis13. This was reflected in a study by
Raskin et al, on 30 patients out of whom 5 had peripheral neuropathy.The study could
not make a convincing association between the middle molecule levels and peripheral
neuropathy11.
After 10 years, Bergstom and Furst came up with a criteria14 for uremic toxins. Those
were,
7 The toxin must be identified chemically and quantitatively measured in
biological fluids.
 The estimated quantity of the toxin should be higher in patients with renal
insufficiency in comparison with normal individuals or patients without renal
insufficiency.
 The concentration of the compound in plasma should have a positive
correlation with the specific uremic symptoms and reduction in the quantity of
the compounds should alleviate the uremic symptoms.
 The manifestations of the toxic compound must be evident at the levels found
in plasma of patients with renal insufficiency.
Uremic neurotoxins refers to  those toxic compounds that are found in plasma
which has damaging properties on the function of nervous system that can be
either central nervous system or peripheral nervous system15,16.
The toxic compounds leading to uremic neuropathy can be categorized into 3
varieties they are,
 Small water soluble compounds like urea &creatinine which are not so toxic
and can be easily removed by dialysis.
 Middle molecules.
 Agents that binds to proteins.
Asymmetric dimethyl arginine (ADMA), a LMW agent is implicated in pathogenesis
of atherogenisis,cerebrovascular accidents and coronary artery disease17,18,19.
8Unfortunately, no single agent has been proven to have toxic effects on peripheral
nerve function.Recent evidences points towards only an anatomical nerve damage
possibly by combined effects of numerous uremic agents20, 21.
Following are the compounds postulated but yet to be validated as a cause of  uremic
neuropathy.
Small water-soluble compounds
 Guanidines
 Asymmetric dimethyl arginine
 Creatinine
 Purines
 Oxalate
 Phosphorus
 Urea
Middle, large molecules
 Advanced glycosylated end products
 Parathyroid hormone
 Oxidation products
 Peptides (beta-endorphin, methionine-enkephalin, beta-lipotropin, granulocyte
inhibiting proteins I and II, degranulation-inhibiting protein, adrenomedullin)
 Beta 2-microglobulin
 Complement factor D
9Protein-bound compounds
 Indoles
 3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid
 Hippuric acid
 Homocysteine
 Indoxylsulfate
 P-cresol
 Polyamines
GUANIDINE COMPOUNDS
Guanidine is one of the normal product of protein metabolism that has been termed as
one of the potential uremic toxin for a long time22. Many different guanidine
compounds are said to present in the brain of an uremic patient23, leading to
conclusions that they may have a role in the pathogenesis of Uremic
encephalopathy24. The postulated mechanism behind guanidine related toxic activity
is that it binds to N-methyl-D-aspartate receptors through guandidino-succinic
acid,activation of which has been implicated in the etio-pathogenesis of various types
of brain damage25,26,27and leading to mitochondrial dysfunction through inhibitory
mechanisms28. In a study on cognitive impairment in hemodialysis patients by
Murray et al, assessment of Guanidine compounds levels in 28 different areas of
brain of uremic patients was done29. An interesting observation was that the
Guanidinosuccinic acid level in uremic brain was 100 fold higher when compared to
control brains which were normal and established a positive correlation between the
brain levels of guanidinosuccinic acid and the extent of uraemia. Guanidinosuccinic
acid when infused into animal brain of the amount found in uremic brain, it lead to
convulsions29.
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The other effects of Guanidines include down regulation of neutrophil superoxide
dismutase and decrease the response of NK cell to IL-230. The Rest of the Guanidines
are analogues of Arginine, and inhibits NO (Nitric oxide) Synthase competitively
which can adversely hamper the removal of advanced glycation end
products(AGEs)31. This causes constriction of blood vessels, rise in Blood Pressure,
ischemic glomerular injury, impairment of immune function32, and neurological
dysfunction33,34. Other LMW compounds that are recently studied and are believed to
be important uremic toxins are cross-linked protein products that contain Diotyrosine
(AOPPs) and asymmetric dimethyl arginine (AMDA)18, 19.
These compounds act as inflammatory mediators,hence are found to be very high
chronic inflammatory states such as CKD. Asymmentricdimethyl arginine also
inhibits NO and has been associated with high plasma levels of homocysteine19.
ADVANCED GLYCATION END PRODUCTS
Advanced glycation end products are either proteins or lipids formed due to exposure
to blood sugar. Since they fall under the toxic ‘Middle Molecules category’, they are
not effectively removed by conventional hemodialysis and there is a progressive
retention of these compounds in patients with End Stage Renal Disease37.
Advanced glycation end products have a causative role in,
 Pathogenesis of Dialysis associated Amyloidosis35.
 Diabetic Nephropathy36.
 Systemic Hypertension in CKD patients by inactivating endothelial nitric
oxide38.
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PROTEIN-BOUND COMPOUNDS (TOXINS)
Polyamines like Spermine are Lipophilic protein bound compounds that are
postulated to be potent uremic toxins that exerts its toxic actions through binding with
NMDA(N-Methyl-D-aspartate)receptors,altering  the tight ionic homeostasis leading
to a terminal pathway for brain cell death 39,40,41. These compounds accumulate in
patients with renal insufficiency and are not effectively removed by haemodialysis.
PARATHYROID HORMONE
In CKD patients there is a state of secondary hyperparathyroidism leading to
increased calcium in the grey matter of the brain leading to characteristic EEG
changes 42,43,44. The hyperparathyroid state also leads to other comorbidities like
coronary artery disease and associated heart failure and cerebrovascular accidents48,49.
Surprisingly these effects were observed in canines administered with parathyroid
hormone while keeping serum calcium and phosphate in normal range.The dogs with
renal insufficiency too displayed similar brain calcium levels and EEG abnormalities
and parathyroidectomy prevented the further progression of brain calcium and EEG
abnormalities,Hence, it was postulated that the parathyroid hormone was essential in
producing uremic neuropathy in canines45, 46.
Primary hyperparathyroidism usually presents as neurologic or psychiatric illness
even in the absence of renal insufficiency50-53 and produce EEG alterations similar to
what is found in Acute Renal Failure42-54. EEG changes appear within eighteen hours
of manifestation of acute renal failure and remains unaltered by dialysis for 2
months42. Parathyroidectomy causes reversal of EEG and psychiatric manifestations
in patients with either primary or secondary hyperparathyroidism, further
consolidating the fact that the parathyroid hormone has a direct adverse action on
12
CNS producing neuropsychiatric manifestations. Renal replacement therapy by
decreasing brain calcium levels has significant positive impact on EEG
abnormilities42-46. The above understanding of pathogenesis of CNS derangement in
hyperparathyroidism gives better picture but is not a comprehensive one. The raised
calcium in tissues like skin, cornea, blood vessels, brain, and heart in those with
hyperparathyroidism shows that parathyroid hormone somehow causes the influx of
calcium into these tissues leading to specific manifestations.
Finally calcium is an indispensible tightly regulated ion that has a very important role
in neurotransmission but any disruption in the calcium levels in the brain can affect
normal neuronal transmission leading to abnormal brain function. Animal and human
studies have perfectly explained the role played by hyperparathyroidism as one of the
important pathogenic process of  uremic encephalopathy and other CNS disturbances
in patient with either ARF or CKD55, 56.
TRANSKETOLASE
It is a Vitamin B1 dependent enzyme found in erythrocytes and nerve tissue that takes
part in  pentose phosphate pathway. The RBC transketolase function appeared to be
depressed due to accumulation of LMW compounds in patients with CKD which
might lead to neuropathy11.This has been evident from the fact that there is an abrupt
rise in transketolase activity in post dialysis blood compared to pre-dialysis blood.The
Neuropathy in pre-dialysis patients could not be attributed only to the depressed
transketolase levels alone, as it is not known whether depressed plasma levels of
other vital enzymes may have had an added role, or even downregulated transketolase
activity is indeed the absolute cause of peripheral neuropathy.Hence it remains as an
important postulated mechanism rather than an established one57, 58, 59.
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MYOINOSITOL
Hypermyoinositolemia in Chronic kidney disease is also implicated in the
pathogenesis of uremic neuropathy. Myoinositol is a water soluble cyclic hexitol that
forms phosphoinositide. These phosphoinositides has increased metabolic activity in
neural tissues affecting the functionality of nervous tissue, hence their accumulation
in CKD is speculated to be an important cause of uremic neuropathy. Structurally it
consists of 6 carbons arranged in a ring containing alcohol group. The molecular
weight is 180 Daltons. Phosphoinositides, a phospholipid compound, can be
synthesized from myoinositol. Their presence in nerve is said to affect its function.
The renal system may have a main role in both myoinositol breakdown and removal.
Studies revealed direct correlation among blood urea nitrogen in blood and
myoinositol levels. High myoinositol levels in blood of rats achieved by feeding a
diet with 35% per-cent myoinositol caused decreased motor NCV(nerve conduction
velocity) in the sciatic nerve. The motor NCV returned to normal levels following
replacement with a diet low in myoinositol. In short, Hypermyoinositolemia may
cause a decrease in nerve conduction velocity but its absolute role in uremic
neuropathy as an uremic toxin has not yet  been fully ascertained7,10,11.
PATHOLOGIC FEATURES:
Uremic neuropathy is primarily an axonopathy caused due to decreased energy
supply by inhibiting enzymes required to maintain energy production as postulated by
Fraser and Arieff.60Pathological research on uremic neuropathy is far and few when
compared to the clinical research. Most of these were sural nerve biopsy studies.
Specific structural derangement in uremic neuropathy is not well understood although
there are many researches; where demyelination is reiterated.Asbury et al1, postulated
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that neuropathy is similar to axonal degeneration of other causes. Since it is an
axonopathy, the nerve fibres which are long are affected compared to shorter fibres
because the metabolic needs of the peri-karyon with a longer fibre is not adequately
met in comparison with the shorter fibres.This results in dying back neuropathy. The
nodes of ranvier which have greater demand due to saltatory conduction and axonal
transport are more affected than other parts of nerve fibres. Nielsen9, postulated that
peripheral nerve derangement was due to disruption of axonal membrane function
and depression of Na+/K+ -activated ATPase by urotoxins.
Bolton10 theorized that membrane derangement may occur in perineurium, acting as a
diffusion barrier between interstitium and the neuron, or within the endoneurium, that
function as a interface between blood and neuron. The end pathway is an direct nerve
damage by urotoxins in the endoneurium causing water and electrolyte shift leading
to either expansion or retraction of space.
A study by Dyck et al7concluded that the uremic neuropathy is an axonopathy
affecting all sizes of nerve fibres but the larger and most distal nerve fibres are
predominantly affected.Although it is believed that segmental demyelination do take
place,rapid nerve regeneration obscures the demyelinating phase. Electron
microscopic changes reveals splitting of the myelin lamellae, and detachment of
lamella from subjacent axolemma with smaller mitochondrial abnormalities.
Neurofilamental or neurotubular derangements are not usually seen. These changes
are found in any number of neuropathy and are not exclusive to Uremic neuropathy8.
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Figure.1 Semithin cut section of Sural nerve with uremic neuropathy having extreme
axonal destruction of big and tiny neurons. The biopsied nerve is stained with
Toluidine blue, 200X magnification.
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Figure 2: Modified Gomori Trichrome-stained sural nerve in uremic neuropathy. The
same nerve showing severe demyelination. 200X magnification.
Figure 3: Muscle biopsy in uremic neuropathy with ATPase stain (pH 9.4). The
normal muscle mosaic pattern was replaced by fiber type grouping, which suggested
chronic denervation and reinnervation. 100X magnification.
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CLINICAL FEATURES
Uremic neuropathy has a vast spectrum of neurological manifestations but the most
common manisfestation of uremic neuropathy is distal symmentrical, mixed motor
and sensory polyneuropathy.Since it is predominantly an axonopathy the longer
axons are affected first manifesting as predominantly involving lower limb more than
the upper limb.The degree of peripheral neuropathy depends on a lot of factors
including the duration of renal insufficiency, eGFR, duration of dialysis and so on.
These variables have little effect on the predominant presentation of uremic
neuropathy8.The restless leg syndrome is characterized by crawling and prickling
sensations in lower limbs particularly more in the evening and are relieved by only
changing the lower limb position.The restless leg syndrome is one of the first
symptoms signifying the involvement of peripheral nerves in uremic neuropathys.11,60
Nielsen61 in his study had seen the above features in 41 out  109 patients with various
stages of CKD. Callaghan as quoted by Asbury and Thomas62 consider them to be an
important early sign of peripheral nerve damage. Whereas some others are reserved in
claiming the restless leg syndrome as a significant symptom since some studies
showed that even an equal amount of patients without peripheral neuropathy can have
restless leg syndrome. Muscle cramps of the extremities is an important symptom in
patient with chronic kidney disease.Muscle cramps can also occur in patients with
acute kidney injury more frequently on patients on haemodialysis.This probably
reflects the fluid shift between the muscle and vascular compartment and the effect of
uremic toxins at the neuromuscular junction11.‘Burning feet’ similar to those occuring
in alcoholics are as per Tytler63, an usual initial sign of neuropathy, but Neilson61
showed that only 6% of 109 victims have those complains, whereas 44 of his patients
experience other sensory features.
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Many patients with uremic neuropathy have poorly defined dysesthesias of distal
extremities  most frequently uncomfortable raw sensations or rarely tingling and
electric shock like sensations precipitated due to subtle digital stimulation,
The other even rarer  vague sensations that uremic patients frequently complain are
band like constrictive feelings compressing the feet and ankles or abnormal feeling of
distension and turbulence of the fingers or toes or the peripheries that are spiralled
into awkward positions8.
The classical signs that are commonly present in patients with peripheral neuropathy
are impaired vibration sense in lower limbs,impaired joint position sense and loss of
deep tendon reflexes8,11,61.The progression of peripheral neuropathy shows wide
variations among patients.With early peaking of symptoms and sings and gradual
progression along with decrease in eGFR or remaining stationary even with
worsening renal failure 8.
Spencer and Schaumberg termed it as ‘dying-back polyneuropathy64. The etiology of
these central-peripheral axonopathies are due to different varieties of toxins. The
axonopathies comprises of neuropathies related to diabetes, multiple myeloma,
amyloidosis, some hereditary polyneuropathies and uremia.64 Spinal cord especially
the posterior column and few more areas of CNS are also involved along with
peripheral nervous system manifestations. The clinical manifestations of distal
axonopathies in CNS as postulated by Schaumberg and Spencer64,65 are:
 Peripheral neuropathy of insidious onset due to continuous exposure to low
concentration of toxin in plasma leading to slowly progressive distal
axonopathy but a normal functioning limb.
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 Large and long axons of the nerves of the lower limbs are affected more in
compared with the upper limb.Sciatic nerve fibres are affected more in
comparison with the others.
 Classical glove and stocking distribution of sensory loss is usually seen
affecting the feet and hands initially.
 Absence of Achilles tendon reflex occurs earlier in comparison with
others.This is due to the fact that axonal fibres to calf muscles are
comparatively larger to the smaller axons to the feet.
 Nerve conduction velocity is significantly affected in demyelinating
lesions,whereas it is normal or slightly affected in case of axonopathy which
can have scattered intact motor fibres.
 CSF findings are within the normal range and since the pathologic alterations
are mostly in distal nerves the nerve roots remain unaffected.
 Uremic neuropathy has a very slow recovery time after the initiation of
dialysis which is characteristic of axonal neuropathies.Axonal neuropathies
have a prolonged recovery time in comparison to demyelinating neuropathies.
 In conjunction with the peripheral large fiber changes there may be associated
changes in the large fibres like pyramidal tracts and spinocerebellar tracts of
central nervous system.The manifestations of central tracts remain less
apparent due to concomitant peripheral neuropathy, however during the
recovery phase of peripheral neuropathy the signs are unmasked and there
may be spasticity or ataxia respectively.
 Many toxic axonopathies have destruction of  neurons in the CNS with
associated destruction in the peripheral nervous system. Clinical features of
damage in the corticospinal and spinocerebellar pathways could not be
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clinically evident if there is extreme peripheral neuropathy. However, on
healing from the neuropathy, there could be spasticity or ataxia.
Spencer and et al 66,67 have demonstrated that most toxic compounds which are
chemically unrelated can cause similar patterns of  distal symmetric polyneuropathy
in both humans and animals.From the wide research that was conducted researchers
believe that there is  a  common end pathway by which toxins cause axonopathy .
Failure to meet the metabolic demands of the distal axon due to decreased enzyme
activity in the presence of toxins followed by decreased delivery of necessary
enzymes to distal axon causing a decreased concentration of enzymes in distal
region.This could all lead to a local blockade of energy dependent axonal transport,
which is the harbinger of a pathway that finally ends in distal nerve fiber
degeneration. Patients with CKD with uraemia who also have associated
comorbidities like Diabetes mellitus, oxidative stress, with accumulation of
superoxides and AGEs(advanced glycation end products) have greater propensity to
have uremic neuropathy9,17.Desert hedgehog mRNA was found to be decreased in
experimental studies involving diabetic neuropathy,which dramatically improved on
treatment with sonic hedgehog igG fusion protein. Such a mode of therapy can be
tried successfully in uremic neuropathy68.
Uremic myopathy is also an important cause of fatigability in CKD patients
frequently causing myopathic weakness and exercise limitation.It is characterized by
muscular atrophy in the final stages69, 70.
Peripheral neuropathy is divided into two broad classes.The first category is a distal
symmetrical mixed sensory-motor polyneuropathy which has a glove and stocking
type of distribution of sensory loss and motor weakness that is more distally in the
extremities.These type of neuropathies are of the dying back variety of axonopathy
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which affects the axons that are the largest and the longest hence involving distal
parts of legs and hands.These distal symmetrical sensory motor mixed
polyneuropathies have toxic compounds, paraneoplastic and  metabolic derangements
as their etiological agents.The other type may be a mononeuropathy or multiple
mononeuropathies which causes a focal isolated lesion of peripheral nerves. The
distal symmetrical polyneuropathy(DSPN) is one of the most common forms of
uremic peripheral neuropathy but uremic neuropathy is not exempt from a wide array
of neuropathic presentations other than DSPN.
Peripheral neuropathy only occurs as an end result to a common pathogenic pathway
and hence is not as a whole unique to a distinct set of disorders like diabetes,chronic
alcoholism,vitamin deficiency states and so on. Uremic polyneuropathy is only a
result of renal insufficiency and accumulation of toxic metabolites,it has no
relationship with the type of renal syndrome that affects the kidney function.Certain
conditions has a simultaneous effect on peripheral nerves as well as other target
organs, these include SLE, amyloidosis, PAN (Polyarteritisnodosa), diabetes mellitus,
hepatic failure and multiple myeloma.The general consensus is that the clinical
manifestation of uremic neuropathy is usually silent if the glomerular filtration rate is
above 12ml/min/1.732BSA.
Most CKD patients with uremic neuropathy who are asymptomatic often show
positive signs for neuropathy on physical examinations.Neuropathies may also
manifest in the form of autonomic dysfunction in the form of impotency,orthostatic
hypotension.Many patients exhibit subclinical neuropathy with decrease in nerve
conduction velocities in the absence of neuropathic symptoms and signs.
Electrophysiological evidence of peripheral neuropathy does not always dictate
anatomical change in nerves .The autonomic dysregulationis often a neglected part of
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uremic neuropathy which may explain the blood pressure fluctuations in patients with
chronic renal insuffeciency71.
To summarize,
 Uremic peripheral neuropathy is an insidious onset slowly progressive distal
neuropathy predominantly presenting with complaints of tingling, prickling, pins
and needles sensations and restless leg syndrome.
o Paraesthesia is one of the common and initial clinical presentations.
o Hyperalgesia is an important symptom.
o Paresis and atrophy of the muscles of lower extremities closely follow
the sensory symptoms .The dying back axons in due time involve
proximal group of muscles and starts to involve the upper limb
o Muscle cramps and restless legs syndrome which is characterized by
bizzare crawling sensations ,quickly resolving with change in limb
posture were reported to involve 67% of patients with uremic
neuropathy patients,although it is also found in patients without
uremic neuropathy.
 In extremely rare cases a GBS like presentation has been reported with rapid
progression to respiratory failure.The limb weakness develops over days to week
with hyporeflexia.
o Compressive mononeuropathies in the form of carpel tunnel
syndrome, cubital tunnel syndrome or peroneal nerve compression at
fibular head can also occur.
o Peripheral nerves which are partly involved are more often the
affected ones in compressive mono neuropathies
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o In amyloidosis deposition of amyloid material can be found in carpel
tunnel  aiding in median nerve compression leading to carpel tunnel
syndrome.
o AV fistulas may compromise blood flow to nerves leading to distal
ischaemic mono neuropathies
EFFECT OF DIALYSIS ON PERIPHERAL NEUROPATHY
The course of peripheral neuropathy in patients with CKD depends mainly upon
eGFR before dialysis11, 72,73,74,75.Peripheral neuropathy if severe before the initiation
of renal replacement therapy has less chance of improvement after hemodialysis or
only improves partially.If the peripheral neuropathy is mild there is a chance of
complete recovery with subsequent cycles of haemodialysis.In patients with ESRD
neuropathy progression remains stationary or improves only slightly.Peritoneal
dialysis due to its advantage in removing middle molecules more effectively seems to
impart a better prognosis in patients with CKD.
INTERMITTENT PERITONEAL DIALYSIS:
Intermittent PD is a time and resource consuming modality of renal replacement
therapy.The usual duration and frequency is 12-24 hour of PD delivered by a cycler
in a hospital or in-center setting, 2-3 times per week.IPD might be a favourable
option for elderly patients who are not fit for Haemodialysis or PD at home due to
associated co-morbidities.The advantages of IPDs are fewer episodes of peritonitis
and better prognosis76. A trial of IPD is often advised in patients for whom palliative
therapy alone might seem inadequate77.
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HEMODIALYSIS:
Patients with CKD on HD have various different manifestations of peripheral
neuropathy with an estimated prevalence of (60%-75%).The most common symptom
of peripheral neuropathy in patients with CKD is paraesthesia found in nearly 6% to
32% of patients. Hemodialysis may halt the progression of uremic neuropathy or may
even cause rapid reversal of neuropathy78-82.
RENAL TRANSPLANTATION
Renal transplantation offers the best possible cure for uremic neuropathy,as evident
from studies which showed to normal clinical and electrophysiological features
following successful renal transplantation.The normal functioning nephrons quickly
detoxifies the plasma leading to initial rapid remission followed by a slow phase. In a
study by Nielson et al conducted on 22 patients with uremic neuropathy who
underwent renal transplantation, There was a rapid recovery in clinical symptoms and
signs and electrophysiological features.The recovery is better in the distal segments
than in the proximal segments. Bolton et al83 emphasized the superiority of Renal
transplantation over hemodialysis in the management of Uremic polyneuropathy.
Whereas, in some cases the injury is permanent and cannot be reversed even on long
term dialysis.84
ELECTRODIAGNOSIS
Electrophysiological study is the Gold standard method in assessing peripheral nerve
function7.Preswick in 1964 85 has demonstrated that decrease in conduction velocity is
a common finding in uremic cases with no external manifestations of neuropathy.
Jebsen86, demonstrated inverse relation between serum creatinine and nerve
conduction velocities.
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Many viable urotoxins have been discovered which has decreased the motor nerve
conduction velocity (MNCV) in experimental animals. 87, 88 The MNCV has been a
principle test for determining neuron function, inspite of fact that it has its own
defects. The associated pitfalls in using MNCVs to diagnose peripheral neuropathy
are
1) Cyclical variations89 in MNCVs that can alternatively show normal values on one
day and abnormal values on another day.
2) These day to day variations can reach as high as 20%.
3) The plasma uremic toxins found in animals which caused a decrease in MNCVs
was not reproducible in humans.90-93Nielson et al,concluded that a decrease in eGFR
and a decrease in motor nerve conduction velocities have a positive correlation with
appearance of clinical neuropathy20,94. In patients not on HD, serum creatinine had a
positive correlation with reduction in nerve conduction velocities.The demonstrated
slowing was typically generalized, motor and sensory, proximal and distal and in both
upper and lower limbs. Several researchers have postulated that before the apparent
decrease in motor nerve conduction velocities there was abnormal late responses
utilizing the tibial and peroneal  H-reflex and F-wave  studies.Hence these H-wave
and F-wave studies are the best and early indicators of electrophysiological
deterioration in patients with chronic kidney disease on long term hemodialysis95,96,97.
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MATERIALS AND METHODS
DESIGN:
Cross sectional study
STUDY POPULATION:
This study was carried out in chronic kidney disease patients attending hemodialysis
unit in our hospital and  patients admitted as in-patients in our medical wards in the
department of General medicine, Government Vellore Medical College and Hospital.
SAMPLE SIZE: 100 Chronic Kidney Disease patients
STUDY PERIOD: OCTOBER 2016 to SEPTEMBER 2017
INCLUSION CRITERIA:
 All patients irrespective of age and sex with the chronic kidney disease.
 eGFR<60ml/min/1.732 determined by
MDRD formula (186.3 x (Creatitine in mg/dl)-1.154 x (Age)-0.203 x (0.742 if
female)
 Ultrasound abdomen evidence of CKD(increased renal cortical echogenicity,
reduced renal cortical thickness or reduced renal length <9cm)
All patients included in the study had chronic kidney disease.
Defined as abnormalities of kidney structure or function for 3 months or longer with
implications for health (KDIGO 2012 CKD NOMENCLATURE). The patients were
further classified based on glomerular filtration rate (GFR) criteria of
30-59ml/min/1.73m2 (Stage III),15-29 ml/min/1.73m2(Stage IV) and GFR
<15ml/min/1.73m2 (Stage V or End Stage Renal Disease).Patients at the time of
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evaluation were on medical management or on Hemodialysis 4hr duration & 3 cycles
per week. None of the patients were on peritoneal dialysis.
EXCLUSION CRITERIA:
• Patient denying Consent
• Patients who had a renal transplant
• Patient with other known cause of peripheral neuropathy such as
Hypothyroidism, Alcoholism, Diabetes Mellitus, Tuberculosis, Hansen’s disease,
Patients on drugs having peripheral neuropathy as established toxicity,
malignancy and vitamin B12 deficiency.
METHODOLOGY:
Patients after satisfying the inclusion criteria were included in the study and were
asked detailed history regarding the duration of uremic symptoms, whether the
patient is already on any renal replacement therapy, if the patient is already on
hemodialysis then the duration of his hemodialysis period was recorded. The patients
were asked to answer questions from MNSI questionnaire and DNSS questionnaire.
Then physical assessment according to MNSI physical assessment chart was carried
out and points filled.
ETHICAL CLEARENCE:
This study was approved by the ethical committee of Government Vellore Medical
College and Hospital, Vellore-11.
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STATISTICAL ANALYSIS:
Statistical analysis was done using the SPSS v16 software. The prevalence is
expressed in percentage (%). Quantitative data were expressed in mean, minimum,
maximum and standard deviation. The qualitative data was expressed by Chi-Square
test. The difference was considered statistically significant if p value was ≤ 0.05.
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OPERATIONAL GUIDELINES:
Peripheral neuropathy was considered to be present if
1. ≥7 points in MNSI QUESTIONNAIRE
2. ≥3 points in MNSI  PHYSICAL ASSESSMENT SCORE
3. ≥1 points in DNS SCORE
Dyslipidemia was considered to be present if:
1. Total cholesterol ≥ 200 mg/dl
2. Triglycerides ≥ 150 mg/dl
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RESULTS AND ANALYSIS
During the period of study, 100 patients diagnosed to have chronic kidney disease
were included in the study after satisfying the inclusion criteria and the following
observations were made.
AGE:
The mean age of the study group was 47.87±14.76 years, with a minimum of 16 years
and a maximum of 84 years. Most of the patients belonged to the age group of 40-70
years of age.
SEX:
Out of 100 cases, there were 58(58.0%) males and 42(42.0%) females. The Male to
Female sex ratio was 1.38:1.
AGE AND SEX DISTRIBUTION:
Of the total number of patients, there were 7 patients who belonged to the age group
of 15-25years, of which there were 4 males and 3 females.A total of 17 patients
belonged to the age group of 26-35 years of age of which there were 8 males and 9
females.There were 16 patients who belonged to the age group of 36-45 years of age
of which there were 9 males and 7 females.27 patients belonged to the age group of
46-55 years of age of which 15 patients were male and 12 patients were female.
A total of 24 patients belonged to the age group of 56 to 65 years of age of which 15
were males and 9 were females.7 patients belonged to the age group of 66 to 75 years
of age of which 5 were males and 2 were females and finally 2 patients belonged to
76 to 85 age group of which both were males.
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TABLE 1:AGE and SEX DISTRIBUTION
AGE
(IN YRS)
MALE FEMALE TOTAL PERCENTAGE(%)
<30 6 7 13 13.0%
31-40 12 9 21 21.0%
41-50 11 10 21 21.0%
51-60 16 12 28 28.0%
61-70 7 4 11 11.0%
>70 6 - 6 6.0%
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AGE and SEX DISTRIBUTION AMONG DIFFERENT CKD SUBCLASS:
TABLE 2: AGE DISTRIBUTION IN CKD SUBCLASSES
AGE in years CKD STAGES
TOTAL
III IV V
<30y 0 3 10 13
30-60y 2 12 46 60
>60y 2 2 23 27
TOTAL 4 17 79 100
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CHART 2:AGE  DISTRIBUTION  AMONG CKD
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TABLE:3GENDER DISTRIBUTION IN CKD SUBCLASSES
GENDER CKD STAGES
TOTAL
III IV V
MALES 2 4 52 58
FEMALES 2 13 27 42
TOTAL 4 17 79 100
CHART:3 GENDER DISTRIBUTION CHART IN CKD SUBCLASSES
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PREVALENCE OF UREMIC PERIPHERAL NEUROPATHY
DISTRIBUTION OF UPN IN THE STUDY POPULATION:
In the study population out of 100 patients, 64 patients were found to have clinical
uremic peripheral neuropathy.The distribution of uremic neuropathy in different sub
groups of study population is as follows.
Out of 100 patients 4 (4.0%)patients belonged to STAGE III CKD out of which 1
patient (25% prevalence) patient was clinically found to have peripheral
neuropathy.17(17.0%) patients belonged to stage IV CKD group out of which 6
patients (35.29% prevalence) clinically tested positive for peripheral neuropathy.The
CKD stage V group which includes both patients on HD and patients not on HD
treatment had the highest number of patients at 79(79.0%) out of which 57 patients
(72.15% prevalence) clinically tested positive for peripheral neuropathy.
TABLE:4 DISTRIBUTION OF UPN IN CKD SUBCLASSES
Clinical UPN -ve Clinical UPN +ve Total
CKD stage III 3 1 4
CKD stage IV 11 6 17
CKD stage V 22 57 79
TOTAL 36 64 100
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AGE DISTRIBUTION:
Among the 13 patients who belonged to the age group of <30 years, none of the
patients were affected by peripheral neuropathy.3 patients among them belonged to
CKD stage 4 group and 10 patients among them belonged to CKD  stage 5 group.
TABLE 5: AGE & UPN DISRIBUTION
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UPN
AGE
UPN
TOTAL
PRESENT ABSENT
<30years 0 13 13
30-60years 39(65%) 21 60
>60years 25(92.5%) 2 27
Total 64 36 100
CHART 4: DISTRIBUTION OF UPN IN CKD SUBCLASSES
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Among the 60 patients who belonged to 30-60years age group 39 patients (65%) were
affected by peripheral neuropathy among them 2 patients belonged CKD stage 3
group,12 patients had stage IV CKD and 46 patients belonged to CKD STAGE V
group.The prevalence of UPN was increased among older patients particularly among
the patients aged more than 60 years.This was statistically significant χ²=32.718 with
2 degree of freedom and the p value was< 0.01.
CHART 5: AGE & UPN DISTRIBUTION CHART
GENDER DISTRIBUTION OF UPN:
In the study population among 58 male patients,43 males(74.13) were affected and
among 42 females,21 patients(50%) were affected by uremic neuropathy. The males
were affected more when compared to females and this was statistically significant.
χ²=6.160 with 1 degree of freedom and p value=0.013(<0.05)
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TABLE 6: GENDER AND UPN DISTRIBUTION
CHART 6:GENDER DISTRIBUTION
CKD STAGE V group:
There were a total of 79 patients who belonged to stage V ckd group, out of which 60
patients were on Hemodialysis and 19 patients were not on Hemodialysis during the
time of study.
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In the HD group out of 60 patients,43 patients(71.6%)  were diagnosed as having
clinical peripheral neuropathy and 17 patients(28.33%)  had not satisfied the
diagnosis of clinical peripheral neuropathy.Within respective sexes 31 males(73.80%)
and 12 females(66.66%) had peripheral neuropathy. Out of the 43 patients, 31
patients who had peripheral neuropathy were males(72.09%) and 12 patients were
females(27.90%) ,whereas, out of 17 patients who did not have peripheral neuropathy
11  were males(26.20%) and 6 were females(33.33%).
TABLE 7: CKD V (on HD) & UPN
CKD V(on HD)
UPN
TOTAL
PRESENT ABSENT
MALE 31(73.80%) 11(26.20%) 42
FEMALE 12(66.66%) 6(33.33%) 18
TOTAL 43 17 60
39
The Chi square value was χ²=3.827 and the p value was exactly 0.05, hence
statistically significant in the study population.
Duration of HD and UPN:
The Minimum duration of HD was 2 months and the maximum duration was 24
months with a mean of 6.50 months±6.829. Out of 43 patients who had a HD
duration between 1-12 months the peripheral neuropathy was present in 28 patients
and in patients having HD duration between 12 to 24 months the peripheral
neuropathy was present in 15 patients
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TABLE 8: UPN & HD DURATION
There presence of peripheral neuropathy and Duration of HD was not statistically
significant. χ²=0.41 with 1 degree of freedom and p value=0.840(p value >0.05).
CKD STAGE V (Not on HD group)
Out of 79 STAGE V CKD patients,19 patients(24.05%) were not on Hemodialysis.
Among them were 10 males(52.63%) and 9 females(47.36%).
A total of 14 patients(73.68%) out of 19 patients had evidence of peripheral
neuropathy and 5 patients(26.31%) did not have peripheral neuropathy.
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1-12 months 28(65.11%) 15 43
13-24 months 15(88.23%) 2 17
TOTAL 43 17 60
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TABLE 9: CKD V (Not on HD) & UPN
UPN
TOTAL
PRESENT ABSENT
MALE 9(90%) 1(10%) 10
FEMALE 5(55.55%) 4(44.44%) 9
TOTAL 14 5 19
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CHART 9: CKD V (Not on HD) & UPN
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Within respective sex, 9 males(90%) had peripheral neuropathy and 5
females(55.55% ) had peripheral neuropathy.Among 14 patients who tested positive
for peripheral neuropathy 64% were males and 35.71% were females.
Prevalence of uremic neuropathy in CKD V not on HD was statistically significant.
χ²=10.999 with 2 degrees of freedom and p value=0.004(<0.01)
PERIPHERAL NEUROPATHY IN STAGE IV CKD:
There were a total of 17 cases who belonged to CKD stage IV, of which there were 4
male and 13 females.Out of the 17 patients 6 patients were diagnosed with peripheral
neuropathy.The prevalence of peripheral neuropathy was 35.29%(p value
<0.01).Among males the prevalence was 50% and among females the prevalence was
30.76%  which was statistically significant χ²=10.999 ,p value=0.004(<0.01)
TABLE 10:CKD IV & UPN
CKD STAGE IV UPN    +ve UPN -ve TOTAL
MALES 2(50%) 2(50%) 4
FEMALES 4(30.76%) 9(69.23%) 13
TOTAL 6(35.29%) 11(64.70%) 17
43
PERIPHERAL NEUROPATHY IN STAGE III CKD:
There were a total of 4 cases who belonged to stage III CKD,among them were 2
males and 2 females.Out of these 4 patients,1 male patient had peripheral
neuropathy.None of the female patient had evidence of clinical peripheral
neuropathy.Hence the prevalence of peripheral neuropathy in STAGE III CKD
patient was 25%.In the study sample 1 of the male patient was affected and none of
the females were affected. The prevalence of peripheral neuropathy in CKD III was
statistically significant. χ²=10.999 with 2 degrees of freedom and a p
value=0.004(<0.01).
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TABLE 11: CKD III & UPN
DURATION OF URAEMIA AND UPN:
The mean duration of uraemic symptoms and peripheral neuropathy was 28.69
months ±10.561 with a minimum of 6 months duration with a maximum of 52
months duration.
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CKD STAGE III UPN    +ve UPN -ve TOTAL
MALES 1 1 2
FEMALES 0 2 2
TOTAL 1(25%) 3(75%) 4
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TABLE 12: DURATION OF URAEMIC SYMPTOMS DISTRIBUTION
DURATION OF
URAEMIA (in
months)
UPN
TOTAL
YES NO
1-6 0 1 1
7-12 0 6 6
13-18 4 9 13
19-24 8 6 14
25-30 15 7 22
31-36 21 3 24
37-42 6 3 9
43-48 8 1 9
>48 2 0 2
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The prevalence of uremic neuropathy was 0% in patients with uremic symptom
duration less than a year. It was 44% in patients with symptom duration ranging from
13 to 24 months,78.26% in patients with duration of 25 to 36 months and 80% in
patients with symptoms more than 3 years.The prevalence of uremic peripheral
neuropathy was more in patients with longer duration of uremic symptoms.This was
statistically significant χ²=28.453 with a p value=<0.01
EGFR AND UPN:
The mean eGFR of the patient was 13.05 ml/min/1.732 BSA ±5.93.the maximum  and
minimum values are 38.39 ml/min/1.732 body surface area and 4.76ml/min /1.732
body surface area respectively.
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TABLE 13:DISTRIBUTION EGFR
eGFR(ml/min/1.73m2BSA)
by MDRD
UPN
TOTAL+ve -ve
<15 57 22 79
15-30 6 11 17
30-60 1 3 4
Total 64 36 100
The prevalence of UPN was 72.15% on patients with eGFR less than 15
ml/min/1.73m2BSA, It was 35.29% in patients with eGFR between 15-
30ml/min/1.73m2BSA
And 25% in patients with eGFR between 30-60 ml/min/1.73m2BSA
The prevalence of peripheral neuropathy increased with decrease in eGFR values. this
was significant statistically. χ²=10.999 with 2 degree of freedom with p value
0.004(<0.01)
SERUM CREATININE AND UPN:
The minimum creatinine value observed was 1.7mg/dl, the maximum creatinine value
observed was 11.3mg/dl. The mean creatinine value was 5.33mg/dl±2.088
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TABLE 14:SERUM CREATININE DISTRIBUTION
Serum creatinine
In mg/dl
UPN
TOTAL+ve -ve
1.5-3 3 8 11
3.1-6 41 22 63
6.1-9 12 6 18
9.1 and above 8 0 8
Total 64 36 100
In the study group 3 patients who had serum creatinine levels between 1.5-3mgs%, 3
patients had  peripheral neuropathy (27.27% prevalence).In patients who had serum
creatinine between 3.1 to 6.0 mgs%, 41 patients(65.07% prevalence) had uraemic
neuropathy and in patients who had serum creatinine between 6.1 and 9mgs%, 12
patients had uraemic neuropathy(66.66% prevalence).
Finally in patients with serum creatinine above 9.1mgs% the prevalence of uraemic
neuropathy was 100%.This was statistically significant χ²=11.027 with 3 degree of
freedom with p value=0.012(<0.05)
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CHART 13: PERIPHERAL NEUROPATHY AND SERUM CREATININE
DISTRIBUTION
MNSI AND URAEMIC PERIPHERAL NEUROPATHY:
The smallest MNSI score  obtained in the study population was 0 and the largest
score was 7 with a mean score of  2.580 with a standard deviation of 2.069.
In the study population, 2 patients (2%) have scored MNSI scores between 1-2.5 out
of 10 and 58 patients(58%) had scored between 3-5.5 out of 10.
No of Patients who had scored between 6-10 points were 34 patients. Rest of the
patients have not scored any points in MNSI
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TABLE 15: THE MOST FREQUENT SIGNS OBSERVED
S.No Abnormal MNSI signs Percentage
1 Appearance of Feet 0%
2 Ulcerations 4.12%
3 Absent ankle relex 40.20%
4 Absent Vibration perception 21.64%
5 Abnormal Monofilament test 34.02%
Absent ankle reflex was the most common finding in the study. The second most
common finding in the study was Abnormal monofilament test which was followed
by absent vibration perception.
Age distribution of MNSI scores:
In the age group of 30-60, 2 patients (3.33%) had scored between 1.25-2.5,
36 patients (60%) had scored between 3-5.5 and 3 patients (5%) had scored greater
than 6.The rest of the patients did not score any points.This was statistically
significant χ²=35.904 with 6 degree of freedom p value:0.000(<0.01)
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TABLE 16: AGE AND MNSI SCORE
MNSI
SCORES
AGE in years
TOTAL
<30 30-60 >60
1.5-2.5 0 2 0 2
3-5.5 0 36 22 58
6-10 0 3 3 6
0 13 19 2 34
TOTAL 13 60 27 100
CHART 14: AGE DISTRIBUTION OF MNSI
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TABLE 17: GENDER DISTRIBUTION OF MNSI
MNSI SCORES
GENDER
TOTAL
MALE FEMALE
1.5-2.5 2 0 2
3-5.5 39 19 58
6-10 4 2 6
NIL 13 21 34
Among 100 patients, 2 males have scored between 1.5-2.5, Thirty nine males have
scored between 3-5.5.Four males have scored between 6-10 and 13 males have not
scored any points. Among females none had scored between 1.5-2.5,Nineteen
patients had scored between 3-5.5.Two patients had scored between 6-10.The
prevalence of MNSI scores among genders were statistically significant χ²=9.119
with 3 degree of freedom and p value =0.028(<0.05)
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CHART 15:GENDER DISTRIBUTION OF MNSI SCORES
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TABLE 18: MNSI SCORES AND CKD STAGES
MNSI
SCORES
CKD STAGES
TOTAL
III IV V
1.5-2.5 0 0 2 2
3-5.5 1 6 51 58
6-10 0 0 6 6
0 3 11 20 34
TOTAL 4 17 79 100
In the study group no patients from CKD stage III & IV have scored MNSI Scores
ranging from 1.5-2.5 or 6-10.Two patients from CKD stage V had scored between
1.5-2.5. One patient from CKD Stage III,6 patients from CKD Stage IV and 51
patients (64.55%) from CKD Stage V has scored between 3-5.5.Six patients (7.5%)
from CKD Stage V group were the sole group of patients who had scored above 6.
The distribution was statistically significant  χ²=13.418 with 6 degrees of freedom
with p value 0.037(<0.05)
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CHART 16:MNSI SCORE DISTRIBUTION CHART  AMONG CKD
SUBCLASSES
Diabetic neuropathic symptom score  and UPN:
The lowest DNSS score obtained was 0 and the maximum score was 3,the mean score
was 0.27 with a standard deviation of 0.548.
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TABLE 19:GENDER AND DNSS
GENDER DNSS TOTAL
0 I II III IV
MALES 44 11 2 1 0 58
FEMALES 33 9 0 0 0 42
Total 77 20 2 1 0 100
Out of 100 patients, 23 patients(23% prevalence) had scored 1 and above in DNSS
which was statistically significant. 20 patients had scored 1 point, out of which there
were 11 males (55%) and 9 females(45%).2 patients had scored 2 points out of which
there were 2 males and none were females. Only one male patient had scored 3
points.
The prevalence of peripheral neuropathy according to DNSS score was statistically
insignificant (p value>0.05) among genders.
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CHART 17:GENDER AND DNSS DISTRIBUTION CHART
Age and DNSS:
Out of 100 patients, none of the patients aged less than 30 years scored in DNSS
questionnaire. Out of 60 patients who belonged to the 30-59 age group, 8 patients had
scored 1 point, 1 patient has scored 2 point and another patient had scored 3 points,
the prevalence of neuropathic symptoms in patient aged 30-59 was 16.66%.In
patients aged 60 and above 12 patients scored 1 point and only one patient scored 2
points and none had scored 3 points. The prevalence of uremic symptoms in patients
aged 60 and above was 48.14% which was statistically significant (p value <0.05),
χ²=16.775 with 6 degree of freedom.
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TABLE 20:AGE& DNSS
DNSS
AGE
<30years 30-59years >59 years
0 13 50 14 77
1 0 8 12 20
2 0 1 1 2
3 0 1 0 1
4 0 0 0 0
Total 13 60 27 100
Most common symptom of uraemic neuropathy according to DNSS scores was
Burning feet closely followed by numbness.Pin prick sensations and gait unsteadiness
were rarer complaints.
TABLE 21: MOST COMMON SYMPTOMS
S.NO Symptoms Total
1. Burning feet 10(43.47%)
2. Numbness 8(34.78%)
3. Pin prick sensation 3(13.04%)
4. Unsteadiness of gait 2(8.69%)
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CHART 18: AGE AND DNSS DISTRIBUTION CHART
CKD STAGE AND DNSS:
Among 4 patients who belonged to CKD STAGE III group, none of the patients had
scored any point, among 17 patient in CKD stage IV group, 3 patients scored 1
point.Among 79 patient in CKD stage V,17 patient scored 1 point,2 patient scored 2
point and 3 patient scored 1 point. The prevalence of peripheral neuropathy according
to DNSS scores were 25.31% in CKD STAGE V,17.64% in CKD STAGE IV and 0%
in CKD STAGE 3, which was statistically not significant (p value 0.425) with 2
degrees of freedom.
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TABLE 22:DNSS and CKD SUBCLASSES
DNSS SCORE
CKD STAGE
TOTAL
III IV V
0 4 14 59 77
1 0 3 17 20
2 0 0 2 2
3 0 0 1 1
Total 4 17 79 100
CHART 19:DNSS AND CKD STAGE CHART
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CKD DURATION AND DNSS:
The prevalence of peripheral neuropathy according to DNSS scores and CKD
duration was not statistically significant, p value=0.550(>0.05), χ²=22.493
eGFR and DNSS:
The prevalence of peripheral neuropathy according to DNSS scores and eGFR was
not statistically significant,p value=0.907(>0.05), with χ²=2.219 ,degree of
freedom=6
DYSLIPIDEMIA DISTRIBUTION:
Age distribution:
Among patients aged <30y two patient had dyslipidemia (15.38%),Twenty two
patients among patients aged 30-60y (36.66%) had dyslipidemia and in patients aged
60 and above 12 patients had dyslipidemia (44.44%).The distribution of dyslipidemia
among patients age was not statistically significant, χ²=3.245 with 2 degree of
freedom p value=0.197(>0.05)
TABLE 23:AGE AND DYSLIPIDEMIA
DYSLIPIDEMIA
AGE
Total
<30 30-60 >60
YES 2 22 12 65
NO 11 38 15 35
Total 13 60 27 100
61
GENDER DISTRIBUTION:
Among the study population, 23 males (39.65%) had dyslipidemia and  13female
patients (30.95%) had dyslipidemia. The distribution of dyslipidemia among genders
was not statistically significant. χ²=0.801 with 1 degree of freedom  and p value was
0.371(>0.05)
TABLE 24:GENDER AND DYSLIPIDEMIA
Dyslipidemia
GENDER
Total
MALE FEMALE
YES 23 13 36
NO 35 29 64
Total 58 42 100
DYSLIPIDEMIA IN CKD SUBSTAGES:
Among the patients none of the stage III patients had dyslipidemia, whereas 4
patients from CKD stage 4 had dyslipidemia (23.52%).Among the CKD stage V
patients 32 had dyslipidemia (40.50%).The prevalence of uremic neuropathy in CKD
Stage did not have any statistical significance. χ²=4.094 with degree of freedom 2 and
p value was 0.129(>0.05)
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TABLE 25:DYSLIPIDEMIA AND CKD STAGES
DYSLIPIDEMIA
CKD STAGE
TOTAL
III IV V
YES 0 4 32 36
NO 4 13 47 64
Total 4 17 79 100
ON HD:
Among HD patients. A total of 25 patients out of 60 patients (41.66%) had
dyslipidemia and 35 patients (58,33%) did not have dyslipidemia. The distribution of
dyslipidemia among HD patients was not statistically significant. χ²=2.091 with 1
degree of freedom. P value was 0.148(>0.05).
TABLE 26:HEMODIALYSIS AND DYSLIPIDEMIA
DYSLIPIDEMIA
ON HD
Total
YES NO
YES 25 11 36
NO 35 29 64
TOTAL 60 40 100
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UPN and Dyslipidemia: Among patients who had dyslipidemia 26 patients(72.22%)
had UPN,whereas 38 patients(59.37%) who were not dyslipidemic did not have
UPN.The prevalence of UPN and dyslipidemia was not statistically significant
χ²=1.651 with 1 degree of freedom.P value=0.199(>0.05)
TABLE 27:DYSLIPIDEMIA AND UPN
DYSLIPIDEMIA
UPN
Total
YES NO
YES 26 10 36
NO 38 26 64
TOTAL 64 36 100
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CHART 20:DYSLIPIDEMIA AND UPN
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BMI and UPN:
Among 100 patients, 2patients (50%) from the BMI group less than 19 had
peripheral neuropathy and two patients did not have peripheral neuropathy. Among
patients who had BMI between 19-25, Forty eight(64.86% prevalence) patients had
UPN, whereas 14 patients (63.63% prevalence) who had a BMI more than 25 had
UPN. This prevalence in the study group was not statistically significant. χ²=0.336
with degree of freedom 2 and the p value was 0.833(>0.05).
TABLE 28:BMI& UPN
BMI
UPN
TOTAL
YES NO
<19 2 2 4
19-25 48 26 74
>25 14 8 22
Total 64 36 100
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CHART 21:BMI and UPN
TABLE 29: DNSS SENSITIVITY AND SPECIFICITY
The DNSS had a sensitivity of 35.94% and a specificity of 100%.This makes DNSS a
poor screening test, hence it could not be used in early diagnosis of uremic peripheral
neuropathy.
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DISCUSSION
Uremic neuropathy is the commonest complication of the uremic syndrome and is
defined as a predominantly distal sensory-motor polyneuropathy that predominantly
affects the distal segments more so in the lower limbs than in the upper limbs which
may occasionally present as a mononeuropathy due to compression, trauma or
ischemia98,99.
The condition is often a silent burden among patients with CKD affecting the quality
of life considerably. The prevalence of peripheral neuropathy due to uraemia may
range from  70-100% in patients with End stage renal disease99-103.Among the non-
dialysis population,one study noted the prevalence  to be 70%104.Patients start
experiencing subtle  symptoms of uremic neuropathy during stage 3 CKD with
peripheral neuropathy prominently affecting stage 4 and ESRD105.
Hundred adult patients with CKD stage 3 or more were included in the present
study.They were patients attending the HD ward for thrice weekly dialysis or patients
admitted in the medical wards of our institution.The mean age of the study population
was 47.87years with a male to female ratio of  1.38:1.
The mean duration of uremic symptoms was 28.69 months.
AGE & GENDER:
In a study by Jedras M et al106, conducted in 51 patients on chronic hemodialysis,
more males were found to be have sensory-motor neuropathy when compared to
women,whereas women were found to have more prevalent autonomic neuropathy
when compared to men. Madhusudhana Babu et al in his study on 74 patients  who
were not on dialysis found that when compared to younger age group patients aged
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more than 65years were affected by peripheral neuropathy.In his study he also noted
that the prevalence of peripheral neuropathy increases among males if eGFR is
<15ml/min/1.73m2.
In our study males were significantly more affected by peripheral neuropathy when
compared to females.This was observed in CKD stage V group(eGFR<15) both in
patients on HD and in patients not on HD.This finding extended to stage IV CKD and
stage III CKD groups.These findings were statistically significant in our study.
In our study it was found that patients aged ≥60 years were predominantly affected by
uremic neuropathy which was statistically very significant(pvalue<0.01).
CLINICAL-INSTRUMENTAL SCREENING TESTS FOR URAEMIC
NEUROPATHY:
Even though Nerve conduction studies are  the gold standard diagnostic modality for
uremic neuropathy,The nature and the lack of such facilities impedes the early
diagnosis.
There are studies which claim that simple screening tools like MNSI scores and
Neuropathic symptom scores  which is a validated  tool for diabetic neuropathy will
also provide an early window of opportunity to diagnose the presence of uremic
neuropathy without having to undergo nerve conduction studies which will pave way
for earlier management.
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Michigan neuropathy screening instrument physical assessment (MNSI):
Mambelli E et al107,conducted a study  on 225 dialysis patients to determine the
prevalence of uremic neuropathy. In their study, all causes inducing secondary
neuropathy were excluded.MNSI scores and Electroneurography of the lower limb
was conducted to compare the sensory nerve conduction velocities and sensory nerve
action potential results with MNSI results.37 patients(16.4%) were identified to have
uremic neuropathy. There was a significant correlation between MNSI scores (>or
equal to 3) between MNSI physical assessment and SCV(r2=0.1959;p<0.034) as well
as SNAP(r2=0.3454;p=0.027) both measured by ENG. He concluded the study by
saying that MNSI could represent a valid and simple clinical-instrumental screening
test for the early diagnosis of Uremic neuropathy in view of an early therapeutic
approach.
In our study of 100 patients which includes CKD patients from stage III to stage V
with or without on hemodialysis. The smallest score obtained was 2 and the largest
score obtained was 7 with a mean score of 2.580±2.069. two patients(2%) have
scored MNSI scores between < 2.5 out of 10 and 58 patients(58%) had scored
between 3-5.5 out of 10.
Further breaking down,1 patient(25% prevalence ) from CKD stage III had scored  >3
in MNSI, six patient(35.29% prevalence) has scored >3 in MNSI. Finally among the
CKD Stage V patients, 51 patients (64.55%) have scored >3 in MNSI.
Among the CKD V patients on HD ,43 patients(71.66% prevalence) had MNSI
scores more than 3 and among  CKD V patients not on HD 14 patients( 73.68%) had
MNSI scores >3.
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The distribution of MNSI scores among different CKD subtype was statistically
significant(χ²=13.418 ,p<0.05).Our study reiterates the fact that MNSI could serve as
a valid test to diagnose Uremic neuropathy with the view that early management may
have a positive impact on the quality of life of the patient.
DNSS SCORES:
In a study by HK Aggarwal et al108 on 100 predialysis patients ,70%  of patients had
scored atleast 1 point in the T-Neuropathy symptom score with maximum score of
17109-111.The scores were found to correlate well with the increase in levels of serum
creatinine107.
Krishnan et al. in their study on 12 ESRD patients graded the neuropathic symptoms
using modified NSS. Each symptom received a score of 1, and the number of
symptoms present in each subset was summed to give a T-NSS. The maximum
possible T-NSS was 9. All 12 patients reported symptoms of neuropathy (mean T-
NSS, 1.9±0.2) 110.
Majority of the patients had at least one neurological symptom (70%), as compared
against the minority (30%) who were asymptomatic. 49% of the patients had a T-NSS
of ≥2 while maximum score of 5 was elicited in 9% of the patients (mean T-NSS,
1.72±1.61).
Laaksonen et al. staged the clinical severity of uremic neuropathy in 21 CKD
patients, using a modified version of the NSS and combined this assessment with
results of nerve conduction studies. The neuropathy symptoms were evaluated using a
modified version of the NSS developed by Dyck. Symptomatic neuropathy (T-NSS
≥2) was observed in 13 patients among the study group (61%)112.
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In our study, We have used a more simplified scoring system, the diabetic neuropathy
symptom score (DNSS) assessing pain, numbness, tingling and ataxia.The maximum
score of DNS is four points, one point or more indicates neurological
abnormalities113.With this scoring system we observed that the prevalence of
neuropathy was 0% in stage III, 17% in stage IV and 25.31% in Stage V.This
distribution was statistically insignificant(p>0.05).
The lowest DNSS score obtained was 0 and the maximum score was 3,the mean score
was 0.27±0.548.
The distribution of DNSS scores and Serum creatinine levels, eGFR levels and
duration of CKD symptoms were statistically insignificant(p value>0.05).Thus our
study concludes that oversimplified symptom scoring systems such as DNSS might
not the best tool for diagnosing uremic neuropathy.T-NSS score and modified NSS
score though laborious might be considered as an effective tool in screening uremic
neuropathy.
CLINICAL MANIFESTATIONS
Symptoms:
Tyler in his study found that burning feet akin to alcoholic peripheral neuropathy are
the earliest manifestation in uremic neuropathy114,whereas Neilson in his study on
109 patients found that only 7 patients complained of burning feet.Patients with
uremic polyneuropathy initially present with sensory symptoms involving the distal
aspect of the lower extremities. Early sensory symptoms include paraesthesia such as
tingling or prickling. Burning pain develops as neuropathy becomes more severe.
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In our study,out of 100 patients only 23 patients(23%) complained of having any
neurological symptom. The most common symptom was burning feet(43.47%),the
least common symptom was unsteadiness of gait(8.6%).
Signs:
Al-Hayk and Bertorini,115 stated that  earliest findings of uremic neuropathy are loss
of Achilles reflex and increased vibrating sensation threshold. Several other studies
concluded that paired vibratory sense in the lower limbs and loss of deep tendon
reflexes, first ankle jerks and then knee jerks, are the usual first signs of
peripheral neuropathy. In comparison to sensory, the distal motor sensory neuropathy
was the common type with chronic kidney disease116.
In our study, the most frequent sign observed was absent ankle reflex (40.20%) which
is consistent with the predominant large fibre involvement in uremic neuropathy,the
next common sign was abnormal monofilament test(34.02%) and absent vibration
perception (21.64%).
PREVALENCE OF URAEMIC PERIPHERAL NEUROPATHY IN
CKDPATIENTS
The prevalence of uremic neuropathy is 60%-100% of patients on dialysis99-103,116.
Neuropathy generally only develops at glomerular filtration rates of less than 12
ml/min/1.732BSA 116.Aggarwal HK et al104,in their study on 100 non dialysis patients,
the prevalence was found to be 70%.
In our study, the prevalence of clinical uremic peripheral neuropathy among 100
CKD patients was 64%.After a subgroup analysis, the prevalence is as follows, In
stage III CKD patients the prevalence of clinical uremic peripheral neuropathy was
72
25%In stage IV CKD patients the prevalence of clinical uremic peripheral neuropathy
was 35.29%
Our study confirms the finding that manifestation of signs and symptoms of uremic
neuropathy is not restricted to patients with eGFR<12ml/min and probably occurs
much earlier. In Stage V CKD patients the prevalence of clinical uremic neuropathy
was 72.15%.Which includes both Pre-dialysis and on dialysis patients.
In stage V CKD(non-Dialysis) patients the prevalence of clinical uremic peripheral
neuropathy was 73.68%.The distribution of peripheral neuropathy among different
CKD subclasses was statistically significant.Confirming the findings in other
studies116.
In stage V CKD(on HD)patients the prevalence of clinical uremic peripheral
neuropathy was 71.6%.which was clinically and statistically significant.The course of
neuropathy is variable in patients undergoing dialysis. Routine hemodialysis have
found not to improve neuropathy in patients with CKD despite decrease in urea and
creatinine levels,this was emphasised by many workers.117,118 Lengthening the time
on dialysis/week (more "square meter hours" i.e. ,membrane area multiplied by
dialysis time) prevents neuropathy.Despite elevated urea and creatinine levels
Peritoneal dialysis improves peripheral neuropathy better than hemodialysis.
These findings correlate with the observations of Asbury,that, in the past decades, the
occurrence of clinically evident neuropathy in patients on chronic dialysis programme
(both haemodialysis and peritoneal dialysis) has become rare, as a result of earlier
institution of treatment, frequent dialysis scheduling and improvement in dialysis
techniques119,120
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DURATION OF URAEMIC SYMPTOMS
Madhusudhana et al, in his study found that prevalence of peripheral neuropathy
increase with long duration of symptoms.
In our study the prevalence was 80% in patients with duration of symptoms more
than 3 years.The prevalence of uremic peripheral neuropathy was more in patients
with longer duration of uremic symptoms.
SERUM CRETININE:
H K Aggarwal et al,in their study on 100 patients found that prevalence of peripheral
neuropathy increased with a raise in serum creatinine, This observation was
confirmed in other studies as well108,111,112,116,121.
In our study, The minmum serum creatinine observed was 1.7mgs% and the
maximum was 11.3mgs% and a mean creatinine value of 5.33mgs%.The prevalence
was 66% in patients with serum creatinine 6.1 to 9mgs% and in patients with serum
creatinine ≥9.1 the prevalence was 100%(p<0.05).
DYSLIPIDEMIA:
CKD leads to a down regulation of lipoprotein lipase and the LDL-receptor, and
increased triglycerides in CKD are due to delayed catabolism of triglyceride rich
lipoproteins, with no differences in production rate122. CKD is associated with lower
levels of apoA-I (due to decreased hepatic expression and higher apoB/apoA-I.
Decreased lecithin-cholesterol acyltransferase (LCAT) activity and increased
cholesteryl ester transfer protein (CETP) activity contribute to decreased HDL-
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cholesterol levels. Beyond decreased HDL cholesterol levels, the HDL in CKD is less
effective in its anti-oxidative and anti-inflammatory functions
As CKD progresses the dyslipidemia often worsens. In an evaluation of 2001-2010
National Health and Nutrition Examination Survey (NHANES), the prevalence of
dyslipidemia increased from 45.5% in CKD stage 1 to 67.8% in CKD stage 4;
similarly, the use of lipid lowering agents increased from 18.1% in CKD stage 1 to
44.7% in CKD stage 4123 Of more than 1000 hemodialysis patients studied only 20%
had “normal” lipid levels (defined as LDL<130 mg/dl, HDL > 40 and triglycerides <
150); of 317 peritoneal dialysis patients only 15% had “normal” lipid levels124. A
larger study evaluating dyslipidemia in > 21,000 incident dialysis patients found 82%
prevalence of dyslipidemia
In our study the prevalence of dyslipidemia was 0% in stage III, 23.5% in stage IV
and 40.5% in stage V CKD. None of these findings were statistically significant.
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LIMITATIONS OF THIS STUDY
1.The long mean duration of uremic symptoms in our patients was probably due to
‘Recall bias’.
2.The positive correlation between MNSI and Electroneuronography as seen by
Mambelli et al, was observed in Italians.There are no reference studies done in Asian
or in any other population groups. Further studies need to be done on different
population subgroups in future.
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CONCLUSION
1) The prevalence of clinical uremic peripheral neuropathy in a series of 100 chronic
kidney disease patients which includes different stages of CKD ranging from stage 3
to stage 5 CKD including those on hemodialysis was 64%.
2)The prevalence of peripheral neuropathy in various subgroups of CKD stages were
25% in stage III CKD ,35.29% in stage IV CKD and 64.55% in stage V CKD.
3)Patients on Hemodialysis had a prevalence of 71.77%,whereas patients not on
hemodialysis who belonged to CKD stage 5group had a prevalence of 73.68%.
4)Clinical neuropathy occurred more commonly in males,older age groups(>60years),
patients with longer duration of uraemic symptoms, elevated serum creatinine levels
and decreasing eGFR levels.
5)The most common symptom was burning foot and the most common clinical sign
observed was loss of ankle reflex.
Prevalence of uremic neuropathy is high in patients with CKD.Since this condition
occurs even in patients not requiring dialysis and worsens with increasing duration of
symptoms, our study emphasises the need for active screening of uremic peripheral
neuropathy in patients with CKD with simple diagnostic tools like MNSI so that early
institution of treatment and further management may play a positive role in the life of
CKD patients.
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PROFORMA
 NAME :
 AGE :
 SEX :
 OCCUPATION :
 ADDRESS :
 IP/OP NO. :
 CBC :
 PERIPHERAL SMEAR :
 RFT :
 RBS :
 LFT :
 TSH :
 LIPID PROFILE :
 ECG :
 USG ABDOMEN :
 CT ABDOMEN (if needed) :
 BP :
 HEIGHT :
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 WEIGHT :
 BMI :
 WAIST CIRCUMFERENCE :
 DURATION OF URAEMIA :
 ON HEMODIALYSIS   (Y/N) :
 IF YES DURATION OF HD :
 ALCOHOLIC : YES NO
 eGFR  by MDRD FORMULA :
 STAGE OF CKD :
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93
DIABETIC NEUROPATHY SYMPTOM SCORE
DNS ITEMS RATE POINTS
Unsteadiness in
walking 0=absent,1=present
Numbness 0=absent,1=present
Burning,aching pain or
tenderness in legs or
feet
0=absent,1=present
Prickling sensations 0=absent,1=present
SCORE:
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PATIENT CONSENT FORM
STUDY DETAIL : A Study on the prevalence of peripheral neuropathy in
patients with chronic kidney disease in GVMCH.
STUDY CENTRE :
PATIENT’S NAME :
PATIENT’S AGE :
IDENTIFICATION NUMBER:
I confirm that I have understood the purpose and procedure of the above
study. I have the opportunity to ask questions and all my questions and doubts
have been answered to my complete satisfaction.
I understand that my participation in the study is voluntary and that I am
free to withdraw at any time without giving reason, without my legal rights
being affected.
I understand that the sponsor of the clinical study, others working on the
sponsor’s behalf, the ethical committee and the regulatory authorities will not
need my permission to look at my health records, both in respect of the current
study and any further research that may be conducted in relation to it, even if I
withdraw from the study I agree to this access. However I understand that my
identity would not be revealed in any information released to third parties or
published, unless as required under the law. I agree not to restrict the use of
any data or results that arise from this study.
I hereby consent to participate in this study.
I hereby give permission to undergo complete clinical examination and
diagnostic tests including haematological, biochemical, radiological tests.
Signature/thumb impression:
Patient’s name and address:                                             Place:
Date:
Signature of the investigator:
Name of the investigator:                                                  Place:
Date:
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: A STUDY ON THE PREVALENCE OF PERIPHERAL
NEUROPATHY IN PATIENTS WITH CHRONIC
KIDNEY DISEASE IN GVMCH
:
/ :
/ :
I.
,
.
II.
,
,
,
.
III.
,
,
,
.
,
.
IV.
.
V.
.
1) /
/
/
2) ,
KEY TO MASTERCHART
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1. Height in centimeters.
2. Weight in kilograms.
3. Duration of CKD in months.
4. CKD STAGE 5=V ; 4=IV ; 3= III
5. On HD  1=Yes; 0=No.
6. Duration of HD in months.
7. eGFR value in ml/min/1.732BSA;calculated by MDRD formula.
8. Serum creatinine in mg/dl.
9. MNSI physical assessment scores out of 10(MAX=10;MIN=0).
10.UPN(Uremic peripheral neuropathy) 1=Present ; 0=Absent.
11.DNSS  scores out of 4(MAX=4;MIN=0).
12.Dyslipidemia 1=Present; 0=Absent.
13.T.C=Total cholesterol in mg/dl.
14.TGL=Triglyceride levels in mg/dl.
15.BMI calculated by weight in Kg/Height in metres2.
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1 40 2 160 60 26 5 1 6 13.57 3.1 5 1 0 1 201 169 23.44 78
2 52 1 166 59 38 5 1 12 14.33 4.6 3 1 1 1 226 112 21.41 72
3 36 1 154 67 33 5 1 10 13.71 5.1 4 1 1 1 212 151 28.25 82
4 45 2 166 88 36 5 1 17 9.72 5.1 4 1 0 1 202 154 31.93 78
5 41 2 156 57 35 5 1 8 14.81 3.6 4 1 0 2 192 142 23.42 76
6 28 1 166 88 7 5 1 4 11.73 6.1 0 0 0 1 278 176 31.93 85
7 36 2 156 57 10 5 1 7 10.91 4.8 0 0 0 1 216 152 23.42 82
8 48 1 150 54 16 5 1 9 11.85 5.5 3 1 0 2 172 132 24 78
9 46 2 176 52 36 5 1 5 9.26 5.3 5 1 0 2 167 122 16.79 73
10 61 1 156 51 41 5 1 3 14.57 4.6 7 1 1 2 190 132 20.96 74
11 65 1 179 76 36 5 1 4 9.36 6.4 4 1 0 1 212 162 23.72 80
12 43 1 164 59 27 5 1 16 14.53 4.7 3 1 0 2 182 141 21.94 75
13 66 1 162 72 35 5 1 12 10.25 5.9 5 1 0 1 210 161 27.43 81
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14 60 1 158 54 25 5 1 13 7.25 8.1 5.5 1 0 2 192 137 21.63 75
15 40 2 160 59 18 5 1 5 11.81 4.4 3.5 1 1 2 182 148 23.05 74
16 68 1 171 91 26 5 1 7 4.86 11.2 6 1 2 1 232 168 31.12 84
17 48 1 168 70 33 5 1 9 13.87 4.8 5 1 3 2 186 132 24.8 78
18 65 2 166 74 41 5 1 12 7.94 5.7 6 1 1 1 210 162 26.85 87
19 65 1 159 57 27 5 1 10 6.48 8.9 5 1 1 2 182 132 22.55 76
20 75 2 154 56 35 5 1 7 8.82 5.2 3 1 1 1 206 154 23.61 79
21 55 1 163 63 29 5 1 2 11.29 5.6 3 1 2 2 193 142 23.71 73
22 18 1 151 52 12 5 1 4 10.77 7.1 0 0 0 2 168 132 22.81 76
23 16 1 157 54 8 5 1 5 13.66 5.9 0 0 0 2 187 122 21.95 72
24 31 1 170 83 26 5 1 20 14.8 4.9 3 1 1 2 190 143 28.72 86
25 60 1 181 69 23 5 1 10 11.1 5.6 3 1 1 2 186 122 21.1 76
26 52 2 151 54 37 5 1 3 12.87 3.9 6 1 0 1 206 166 23.68 80
27 50 2 170 69 34 5 1 7 11.59 4.3 5 1 0 2 182 132 23.88 73
28 36 1 165 70 26 5 1 6 12.31 5.6 0 0 0 2 189 148 25.71 78
29 62 2 144 44 45 5 1 7 9.11 5.1 5 1 1 2 183 137 21.22 69
30 49 1 160 57 27 5 1 9 13.81 4.8 6 1 0 2 184 146 22.27 83
31 32 1 164 67 16 5 1 12 12.61 5.6 2 0 0 2 191 147 25 88
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32 35 1 160 55 26 5 1 23 10.42 6.5 6 1 0 2 172 137 21.48 76
33 50 1 163 61 28 5 1 12 12.83 5.1 3 1 0 1 271 167 22.96 86
34 40 1 164 70 25 5 1 8 14.39 4.8 0 0 0 1 221 162 26.03 90
35 63 1 155 51 46 5 1 8 5.09 10.9 4 1 1 2 185 139 21.23 71
36 84 1 165 61 22 5 1 10 13 4.6 0 0 0 1 261 171 22.41 74
37 45 1 160 60 36 5 1 11 7.91 7.9 5 1 0 1 268 162 23.44 84
38 50 2 167 55 15 5 1 14 12.01 5.4 4 1 0 2 161 103 19.72 73
39 57 1 159 56 47 5 1 6 8.39 7.2 5 1 0 2 187 138 22.15 70
40 46 1 175 61 36 5 1 18 9.86 6.5 3 1 0 2 173 129 19.92 69
41 29 2 168 67 28 5 1 21 8.55 6.2 0 0 0 2 191 132 23.74 76
42 52 1 155 69 21 5 1 19 10.97 5.8 3 1 0 1 254 169 28.72 91
43 22 1 175 64 25 5 1 17 14.49 5.3 0 0 0 2 175 126 20.9 68
44 38 1 167 72 19 5 1 19 11.93 5.7 3 1 0 1 161 112 25.82 83
45 35 1 156 54 6 5 1 5 8.7 7.6 0 0 0 2 183 137 22.19 76
46 68 2 166 56 35 5 1 12 10.07 4.6 5 1 1 2 179 131 20.32 68
47 36 1 159 53 23 5 1 10 13.41 5.2 3 1 0 2 176 121 20.96 76
48 35 2 167 64 37 5 1 8 14.82 3.7 0 0 0 2 198 141 22.95 82
49 53 1 149 51 24 5 1 20 6.11 9.6 4 1 0 1 239 162 22.97 74
100
50 56 1 162 55 44 5 1 16 5.51 10.4 5 1 0 1 211 152 20.96 72
51 28 1 160 59 10 5 1 7 14.76 5 0 0 0 2 165 121 23.05 85
52 48 1 159 72 23 5 1 12 11.37 5.7 3 1 0 1 249 163 28.48 90
53 58 1 153 40 35 5 1 14 14.38 4.5 3 1 0 2 174 135 17.09 65
54 17 1 155 62 15 5 1 10 13.24 6 0 0 0 2 171 126 25.81 85
55 48 2 167 62 13 5 1 9 8.98 5.4 0 0 0 1 205 156 22.23 79
56 47 1 169 60 30 5 1 23 11.9 5.5 4 1 0 2 179 132 21.01 74
57 32 2 169 59 13 5 1 10 11.45 4.7 0 0 0 2 162 120 20.66 78
58 60 1 176 65 46 5 1 24 6.26 9.2 4 1 0 1 208 162 20.98 70
59 60 1 170 85 39 5 1 15 6.67 8.7 3 1 0 1 331 182 29.41 96
60 21 2 155 77 22 5 1 8 9.23 6.1 0 0 0 1 301 182 32.05 105
61 35 1 153 45 19 3 0 0 38.39 2.1 0 0 0 2 168 132 19.22 68
62 32 1 151 68 24 4 0 0 23.21 3.3 0 0 0 1 298 185 29.82 88
63 72 1 170 60 38 3 0 0 31.43 2.2 3 1 0 2 185 134 20.76 77
64 40 1 164 62 11 4 0 0 15.12 4.6 0 0 0 2 192 139 23.05 83
65 57 1 162 56 31 5 0 0 10.77 5.8 5 1 1 2 165 127 21.34 76
66 53 1 163 54 35 4 0 0 17.27 3.9 3 1 0 2 156 121 20.32 68
67 60 1 159 72 25 5 0 0 9.34 6.5 3 1 0 1 365 198 28.48 88
101
68 52 1 163 63 28 5 0 0 11.91 5.4 3 1 0 1 217 162 23.71 85
69 45 1 159 56 17 5 0 0 8.8 7.2 2 0 0 2 186 128 22.15 82
70 40 2 167 48 41 3 0 0 31.12 1.9 0 0 0 2 179 131 17.21 65
71 50 2 170 66 35 5 0 0 12.97 3.9 0 0 0 2 169 108 22.84 79
72 63 2 163 58 51 4 0 0 18.92 2.7 4 1 1 1 201 156 21.83 75
73 57 2 162 57 34 5 0 0 14.8 3.4 3 1 0 2 198 140 21.72 76
74 60 2 165 56 52 5 0 0 11.17 4.3 4 1 1 2 173 129 20.57 67
75 58 2 162 63 18 4 0 0 25.71 2.1 0 0 0 1 233 165 24.01 87
76 48 2 161 60 36 5 0 0 6.34 7.3 3 1 1 2 186 147 23.15 85
77 32 2 158 54 22 4 0 0 19.99 2.9 0 0 0 2 176 123 21.63 73
78 47 1 162 55 36 4 0 0 15.4 4.4 4 1 1 2 177 135 20.96 69
79 55 2 171 56 43 4 0 0 16.58 3.1 3 1 0 2 165 148 19.15 74
80 60 2 164 57 29 4 0 0 17.59 2.9 4 1 1 2 197 133 21.19 80
81 60 2 166 52 36 5 0 0 6.93 6.5 3 1 0 2 166 129 18.87 68
82 23 2 153 58 13 5 0 0 14.33 4.1 0 0 0 2 185 142 24.78 86
83 60 2 156 49 44 3 0 0 32.58 1.7 0 0 0 2 169 135 20.13 72
84 54 2 171 62 29 4 0 0 17.97 2.9 0 0 0 2 179 144 21.2 76
85 55 2 173 63 35 4 0 0 15.43 3.3 3 1 0 2 173 126 21.05 79
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86 20 2 173 58 42 5 0 0 13.24 4.5 0 0 0 2 186 121 19.38 64
87 27 2 170 60 27 4 0 0 15.62 3.7 0 0 0 2 164 119 20.76 70
88 33 2 169 55 15 4 0 0 27.32 2.2 0 0 0 2 188 140 19.26 71
89 35 2 155 63 23 5 0 0 13.94 3.9 0 0 0 1 265 165 26.22 89
90 72 1 154 70 46 5 0 0 8 7.2 3 1 0 1 324 198 29.52 96
91 54 2 162 63 28 5 0 0 11.41 4.3 3 1 0 1 236 185 24.01 84
92 50 2 166 58 31 4 0 0 19.83 2.7 0 0 0 2 185 148 21.05 75
93 43 2 157 64 27 4 0 0 16.8 3.2 0 0 0 1 225 176 25.96 82
94 60 1 169 57 43 5 0 0 14.28 4.5 3 1 0 2 177 135 19.96 69
95 29 2 173 60 33 4 0 0 15.39 3.7 0 0 0 2 189 122 20.05 71
96 28 2 162 47 17 4 0 0 18.33 3.2 0 0 0 2 178 133 17.91 68
97 72 1 171 65 24 5 0 0 4.76 11.3 5 1 1 2 168 125 22.23 81
98 53 1 168 72 18 5 0 0 6.42 9.2 3 1 1 1 208 154 25.51 83
99 63 1 170 62 24 5 0 0 5.5 10.2 4 1 0 1 289 168 21.45 79
100 78 1 158 54 36 5 0 0 9.91 5.9 3 1 0 2 187 130 21.63 72
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